New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:39 EDTRHHBY, REGNFears about Regeneron overdone, says RBC Capital
After meeting with with a retina key opinion leader, RBC Capital does not believe that there is a full-scale shift away from Regeneron's (REGN) Elyea to Roche's (RHHBY) Avastin. The firm thinks that Regeneron has a number of upcoming potential major positive catalysts and recommends buying the stock on any pullbacks. It keeps a $349 price target and Outperform rating on the shares.
News For REGN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 10, 2016
07:18 EDTREGNRegeneron price target lowered to $489 from $659 at Brean Capital
Subscribe for More Information
February 9, 2016
16:53 EDTREGNOn The Fly: Top stock stories for Tuesday
Stocks began the day sharply lower in the wake of a stock market selloff in Japan, but the domestic averages quickly gathered themselves and were in positive territory before long. From there stocks spent most of the day searching for direction but not moving far from the flat line. A late day rally made it seem like a green close was possible, but the averages could not hold and the market's losing streak continued, though the losses were modest. ECONOMIC EVENTS: In the U.S., wholesale sales dipped 0.3% in December, while inventories fell 0.1%. The Labor Department's Job Openings and Labor Turnover Survey showed job openings rose 261,000 in December to about 5.61M. In Asia, most major markets remain closed for Chinese New Year, but one of the exceptions, Japan, saw its main indexes plunge, as the Nikkei dropped 5.4% and the Topix fell 5.5%. COMPANY NEWS: Class A shares of 21st Century Fox (FOXA) declined 1.85% to $24.14 after the company reported lower than expected second quarter revenue and cut its 2016 outlook, while peer Viacom (VIAB) tumbled 21.5% to $32.86 following its own revenue miss. The largest name in the space, Disney (DIS), rose fractionally ahead of its own earnings report after the bell, but its shares dipped nearly 3% in after-hours trading following the company's report... Deutsche Bank (DB) continued its recent slide, falling another 1% in New York trading despite a report of co-CEO John Cryan telling employees in a memo that the bank is "absolutely rock-solid." The stock came well off its lows in afternoon trading, however, after Financial Times said the German giant is considering buying back several billion euros of its debt... Anadarko Petroleum (APC) lost 7.5% to $37.06 after slashing its dividend to 5c from 27c per share, with Anadarko Chairman and CEO Al Walker defending the step as "the appropriate action to take in the current environment." MAJOR MOVERS: Among the notable gainers was Boston Scientific (BSX), which advanced 5% to $16.87 after announcing that the government's Medicare and Medicaid will cover its Watchman cardiac device. Also higher was Salesforce (CRM), which gained 6.1% to $57.33 after being upgraded to Hold from Underperform at Jefferies, with the research firm arguing that Salesforce is seeing improved traction in enterprise and continued solid mid-market performance. In addition, Wyndham (WYN), Spirit Airlines (SAVE) and Masco (MAS) rose 2.6%, 5.8% and 8.2%, respectively, following their quarterly earnings reports. Among the noteworthy losers was ITC Holdings (ITC), which fell 1.85% to $38.65 after agreeing to be acquired by Fortis in a cash-and-stock deal valued at roughly $11.3B. Also lower were Regeneron (REGN) and Wendy's (WEN), which lost 6.3% and 4.3%, respectively, after announcing their quarterly results. INDEXES: The Dow fell 12.67, or 0.08%, to 16,014.38, the Nasdaq lost 14.99, or 0.35%, to 4,268.76, and the S&P 500 declined 1.23, or 0.07%, to 1,852.21.
12:25 EDTREGNRegeneron price target lowered to $443 from $607 at Piper Jaffray
Subscribe for More Information
09:25 EDTREGNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Wendy's (WEN), up 3.5%. ALSO HIGHER: ITC Holdings (ITC), up 1.1% after being acquired by Fortis for in a deal valued at $11.3B... Kinross Gold (KGC), up 2.9% after being upgraded to Outperform from Neutral at Credit Suisse... Boston Scientific (BSX), up 3.1% after announcing that Medicare will cover Watchman left atrial appendage closure Device. DOWN AFTER EARNINGS: Regeneron (REGN), down 7.2%... Twenty-First Century Fox (FOXA, FOX), down 6.7% and 2.6%, respectively... CVS Health (CVS), down 3.5%... Viacom (VIAB), down 3.2%. ALSO LOWER: Constant Contact (CTCT), down 3.3% after Bloomberg reported that Endurance International (EIGI) withdrew a $735M loan Monday that was intended to help fund its $1.1B takeover of the company... Paypal (PYPL), down 2.4% after announcing a Chief Technology Officer transition.
06:33 EDTREGNRegeneron sees FY16 U.S. Eylea revenue up 20% over FY15
06:32 EDTREGNRegeneron reports U.S. Eylea revenue $746M vs. $518M last year
Subscribe for More Information
06:32 EDTREGNRegeneron reports Q4 EPS $2.83, consensus $3.36
Subscribe for More Information
February 8, 2016
14:28 EDTREGNNotable companies reporting before tomorrow's open
Subscribe for More Information
07:25 EDTREGNBiotech Industry Organization to hold a conference
Subscribe for More Information
06:28 EDTRHHBYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 5, 2016
09:26 EDTREGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:06 EDTREGNRegeneron resumed with an Outperform at Leerink
Subscribe for More Information
February 4, 2016
16:37 EDTREGNRegeneron reinitiated with an Outperform at Leerink
Target $534.
February 3, 2016
14:32 EDTRHHBYPacific Biosciences deal with Roche may take time to get done, says Cantor
Subscribe for More Information
February 2, 2016
16:23 EDTRHHBYOn The Fly: Top stock stories for Tuesday
Stocks began the session in negative territory and remained there throughout the entire session. The early weakness was attributed to oil prices, which were down early and never recovered during the day. The losses of more than 5% brings the loss over the past two days to more than 10%, pushing WTI crude back below $30 a barrel and squashing equities in the process. Any hope that oil prices would de-couple from stock prices will have to wait another day as the two continue to move in lockstep with each other. Even a solid earnings report from tech bellwether Alphabet (GOOG) could not help the market. ECONOMIC EVENTS: In the U.S., the economic calendar was quiet. In Europe, statistics agency Eurostat reported that unemployment across the eurozone decreased by 49,000 to a total of 16.75M in December dropping the unemployment rate to its lowest since September 2011 at 10.4%. In central bank news, the Reserve Bank of Australia and Reserve Bank of India both held their benchmark interest rates steady, as expected. COMPANY NEWS: Class A shares of Alphabet (GOOGL) advanced 1.3% to $780.91 after its better than expected quarterly results were followed by analysts around Wall Street hiking their price targets for shares, including Deutsche Bank analyst Ross Sandler, who raised his target on the parent of Google to $1,080 from $900... Exxon Mobil (XOM) reported better than expected revenue and profits in the fourth quarter, but its shares slid 2.2% to $74.61 amid the renewed weakness in oil prices. Shares of fellow oil major BP (BP) plunged 8.5% to $29.02 in New York trading after reporting a steep quarterly loss, largely due to $2.6B in charges related to impairments of Upstream assets as well as restructuring... Ford (F) shares fell 4.6% after the company reporting that its U.S. sales declined 3% last month versus a year ago. Peer General Motors (GM) slid 1.5% after reporting that its U.S. sales grew 0.5% in January... Dow Chemical (DOW) jumped 5.75% to $45.03 after posting better than expected earnings and revenue. Of note, Dow CEO Andrew Liveris said he plans to transition out of the company when it completes its planned merger with DuPont (DD). MAJOR MOVERS: Among the notable gainers were Michael Kors (KORS) and Mattel (MAT), which rose nearly 24% and almost 14%, respectively, following their earnings reports. Also higher was Pacific Biosciences (PACB), which jumped 24% to $12.67 after Reuters said Roche (RHHBY) has recently approached the company to discuss a potential acquisition. Among the noteworthy losers following earnings were Integrated Device (IDTI), which fell 26.8%, ADT (ADT), which dropped 15.7%, and Royal Caribbean (RCL), which declined 15.2%. INDEXES: The Dow fell 295.64, or 1.8%, to 16,153.54, the Nasdaq lost 103.42, or 2.24%, to 4,516.95, and the S&P 500 declined 36.35, or 1.87%, to 1,903.03.
15:12 EDTRHHBYRoche approached Pacific Biosciences about possible acquisition, Reuters says
Subscribe for More Information
15:10 EDTRHHBYRoche approached Pacific Biosciences about possible acquisition, Reuters says
08:36 EDTRHHBYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
11:02 EDTRHHBYRoche: Updated cervical cancer screening guidelines support use of cobas test
Roche announced that recently updated cervical cancer screening guidelines from the American College of Obstetricians and Gynecologists support the use of its cobas HPV Test for primary cervical cancer screening as an alternative to current cytology-based cancer screening methods in women 25 and older. The College's revised Practice Bulletin 157, published in the January issue of Obstetrics & Gynecology, reinforces similar guidance issued in 2015 by the Society for Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology. The cobas HPV Test was approved by the FDA in 2011 for use in screening women 21 and older with unclear Pap test results and for co-testing with a Pap test in women 30 and older. The FDA approved it for first-line primary cervical cancer screening for women 25 and older in April 2014 following a unanimous recommendation from the independent Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee. Currently utilized by more than 250 labs in the U.S., the cobas HPV Test is the only test approved in the U.S. for all three HPV testing options now supported by three major medical societies.
January 31, 2016
16:13 EDTRHHBYGenentech receives orphan designation for Avastin in mesothelioma
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use